Autopsy report · NCT00913393
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
Cause of deathFunding or business
“Study was terminated early for business purposes and as a result of a strategic decision to shift focus to another indication.”
Life of this trial
- Registered 4 months after it had already started.
- Ran for about 1 year 4 months before it stopped.
- 46 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Kyntra Bio
- Sponsor type
- Industry
- Conditions
- Type 2 Diabetes Mellitus; Diabetic Nephropathy; Diabetic Kidney Disease
- Interventions
- FG-3019; FG-3019; Placebo
- Participants
- 46
- Sites
- 28
- Countries
- United States
Trials that died the same way
- Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
“Study terminated due to business and strategic decision.” - A Study of LY3549492 in Healthy Weight Adult Participants
“Study terminated for strategic business reasons” - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
“The study was terminated due to strategic business reasons.” - A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
“Study terminated as part of strategic considerations” - Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
“Study was terminated early for strategic reasons. Only Part I of the study was completed.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.